Calendario›INCY›INCB040093

INCB040093

Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies

Ensayo de INCYTE CORP en B-cell Malignancies (del registro, en inglés).

Fase

Fase 1

Estado

Completado

Participantes

121

previstos

Centros

6

Fin del objetivo primario

feb 2026

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, no aleatorizado, abierto. Comenzó en jun 2013.

Qué mide

Safety and tolerability of INCB040093 as monotherapy and when given in combination with itacitinib as determined by clinical laboratory assessments, physical exams, 12-lead ECG and summary of adverse events (Measured every 3 weeks until progression.) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThe study will be conducted in three parts. Part 1 is a dose escalation phase to determine the maximum tolerated dose (MTD) of INCB040093, a PI3Kδ inhibitor, or a tolerated, pharmacologically active dose; Part 2 will evaluate the combination of INCB040093 and itacitinib (INCB039110), a JAK1 inhibitor, to determine the MTD of the combination or a tolerated dose that produces substantial pharmacologic inhibition of both targets; Part 3 will further evaluate the chosen doses of INCB040093 alone and in combination with itacitinib (INCB039110) in subjects with relapsed/refractory B-cell malignancies.

Más ensayos de INCY

Todos los de INCY, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT01905813), actualizada en may 2026.